Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
BURLINGTON, Mass., April 07, 2016 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will provide a company overview at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 3:40 p.m. EDT in New York, NY.
To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with OA. The company's lead product candidate, Zilretta, is being investigated for its potential to provide improved analgesic therapy for the millions of U.S. patients who receive IA injections for knee OA annually. The company is also investigating another product candidate, FX007, a locally administered TrkA receptor antagonist for post-operative pain.
Investor Contact David Carey Lazar Partners LTD T: 212-867-1768 [email protected] Media Contact Mariann Caprino TogoRun T : 917.242.1087 [email protected] Corporate Contact Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected]
